GALE Galena Biopharma Inc

GALE FRAUD NOTICE: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action – GALE

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Galena Biopharma, Inc. securities (NASDAQ:GALE) from August 11, 2014 through January 31, 2017, both dates inclusive (the “Class Period”) of the April 14, 2017 lead plaintiff deadline in the class action filed by the Rosen Firm. This first filed lawsuit seeks to recover damages for Galena investors under the federal securities laws.

To join the Galena class action, go to http://www.rosenlegal.com/cases-1054.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) as a result, Defendants’ statements about Galena’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1054.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
20/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galena Biopharma Inc

 PRESS RELEASE

Deadline Alert: GPM Reminds Investors of the April 14 Deadline in the ...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 14, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Galena Biopharma, Inc. (“Galena” or the “Company”) (NASDAQ: GALE) securities between August 11, 2014 and January 31, 2017, inclusive (the “Class Period”). Galena investors have until April 14, 2017 to file a lead plaintiff motion. On November 9, 2015 Galena disclosed plans to “divest its commercial busine...

 PRESS RELEASE

DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadlin...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Galena Biopharma, Inc. (Nasdaq: GALE) (“Galena” or the “Company”) securities during the period between August 11, 2014 through January 31, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 14, 2017 to s...

 PRESS RELEASE

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Galena Biopharma, Inc. (Nasdaq: GALE) (“Galena” or the “Company”) securities during the period between August 11, 2014 through January 31, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 14, 2017 to s...

 PRESS RELEASE

GALE FRAUD NOTICE: Rosen Law Firm Reminds Galena Biopharma, Inc. Inves...

NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Galena Biopharma, Inc. securities (NASDAQ:GALE) from August 11, 2014 through January 31, 2017, both dates inclusive (the “Class Period”) of the April 14, 2017 lead plaintiff deadline in the class action filed by the Rosen Firm. This first filed lawsuit seeks to recover damages for Galena investors under the federal securities laws. To join the Galena class action, go to http://www.rosenlegal.com/cases-1054.html or call Phillip...

 PRESS RELEASE

CORRECTING and REPLACING Glancy Prongay & Murray LLP Files Securities ...

LOS ANGELES--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: GLANCY PRONGAY & MURRAY LLP FILES SECURITIES CLASS ACTION LAWSUIT AGAINST GALENA BIOPHARMA, INC. Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the “Class”) consisting of persons and entities that acquired Galena Biopha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch